CHSR 📈 UBS(Lux)Fund Solutions – - Overview
Exchange: XETRA • Country: Germany • Currency: EUR • Type: Etf • ISIN: LU2250132763 • Switzerland Equity
CHSR: ETF, Switzerland, Equities, Index, Fund, Investment
‣ Company URL: http://www.credit-suisse.com ‣ Domicile: Luxembourg ‣ Index Name: Morningstar Switzerland TME NR CHF
Additional Sources for CHSR ETF
CHSR ETF Overview
| Market Cap in USD | 178m |
| Category | Switzerland Equity |
| TER | 0.30% |
| IPO / Inception | 2021-02-26 |
CHSR ETF Ratings
| Growth 5y | 39.6% |
| Fundamental | - |
| Dividend | - |
| Rel. Strength Industry | -59 |
| Analysts | - |
| Fair Price Momentum | 12.89 EUR |
| Fair Price DCF | - |
CHSR Dividends
No Dividends PaidCHSR Growth Ratios
| Growth Correlation 3m | -73.6% |
| Growth Correlation 12m | 86.7% |
| Growth Correlation 5y | 51.4% |
| CAGR 5y | 4.77% |
| CAGR/Mean DD 5y | 0.63 |
| Sharpe Ratio 12m | 0.17 |
| Alpha | -11.19 |
| Beta | 0.58 |
| Volatility | 10.52% |
| Current Volume | 1.8k |
| Average Volume 20d | 6.4k |
What is the price of CHSR stocks?
As of December 22, 2024, the stock is trading at EUR 14.31 with a total of 1,757 shares traded.
Over the past week, the price has changed by -2.25%, over one month by -0.90%, over three months by -4.03% and over the past year by +7.65%.
As of December 22, 2024, the stock is trading at EUR 14.31 with a total of 1,757 shares traded.
Over the past week, the price has changed by -2.25%, over one month by -0.90%, over three months by -4.03% and over the past year by +7.65%.
Is UBS(Lux)Fund Solutions – a good stock to buy?
Partly, yes. Based on ValueRay Analyses, UBS(Lux)Fund Solutions – (XETRA:CHSR) is currently (December 2024) ok to buy, but has to be watched. It has a Growth Technical Rating of 39.63 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CHSR as of December 2024 is 12.89. This means that CHSR is currently overvalued and has a potential downside of -9.92%.
Partly, yes. Based on ValueRay Analyses, UBS(Lux)Fund Solutions – (XETRA:CHSR) is currently (December 2024) ok to buy, but has to be watched. It has a Growth Technical Rating of 39.63 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CHSR as of December 2024 is 12.89. This means that CHSR is currently overvalued and has a potential downside of -9.92%.
Is CHSR a buy, sell or hold?
UBS(Lux)Fund Solutions – has no consensus analysts rating.
UBS(Lux)Fund Solutions – has no consensus analysts rating.
What are the forecast for CHSR stock price target?
According to ValueRays Forecast Model, CHSR UBS(Lux)Fund Solutions – will be worth about 14.1 in December 2025. The stock is currently trading at 14.31. This means that the stock has a potential downside of -1.19%.
According to ValueRays Forecast Model, CHSR UBS(Lux)Fund Solutions – will be worth about 14.1 in December 2025. The stock is currently trading at 14.31. This means that the stock has a potential downside of -1.19%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 14.1 | -1.2% |